Larimar Therapeutics to Attend Investor Conferences

BALA CYNWYD, Pa., Aug. 27, 2024 - Larimar Therapeutics, Inc. (Nasdaq: LRMR), a biotechnology firm dedicated to creating therapies for complex rare diseases, has announced its participation in upcoming investor meetings. Executives from Larimar will engage in one-on-one discussions at the Wells Fargo Healthcare Conference in Boston, MA, from September 4-6, 2024, and at the H.C. Wainwright 26th Annual Global Investment Conference in New York, NY, from September 9-11, 2024.

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering treatments for rare and complicated diseases. Their chief drug candidate, nomlabofusp, aims to treat Friedreich's ataxia. Additionally, Larimar is leveraging its intracellular delivery platform to create new fusion proteins to tackle other rare diseases associated with deficits in intracellular bioactive compounds.